Revenue (Quarterly) Chart

View Revenue (Quarterly) for SIGA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Revenue (Quarterly) Chart
Start Trial

Historical Revenue (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 41.00M
March 31, 2026 6.243M
December 31, 2025 3.794M
September 30, 2025 2.62M
June 30, 2025 81.12M
March 31, 2025 7.041M
December 31, 2024 81.47M
September 30, 2024 10.01M
June 30, 2024 21.81M
March 31, 2024 25.43M
December 31, 2023 116.48M
September 30, 2023 9.235M
June 30, 2023 5.878M
March 31, 2023 8.323M
December 31, 2022 11.36M
September 30, 2022 72.21M
June 30, 2022 16.67M
March 31, 2022 10.54M
December 31, 2021 115.36M
September 30, 2021 4.846M
June 30, 2021 8.653M
March 31, 2021 4.814M
December 31, 2020 37.73M
September 30, 2020 44.26M
June 30, 2020 40.35M
Date Value
March 31, 2020 2.620M
December 31, 2019 4.264M
September 30, 2019 8.111M
June 30, 2019 3.908M
March 31, 2019 10.46M
December 31, 2018 1.569M
September 30, 2018 471.08M
June 30, 2018 2.661M
March 31, 2018 1.748M
December 31, 2017 1.412M
September 30, 2017 1.390M
June 30, 2017 4.265M
March 31, 2017 5.202M
December 31, 2016 7.158M
September 30, 2016 4.658M
June 30, 2016 1.901M
March 31, 2016 1.270M
December 31, 2015 4.189M
September 30, 2015 1.327M
June 30, 2015 1.468M
March 31, 2015 1.192M
December 31, 2014 0.8404M
September 30, 2014 1.099M
June 30, 2014 0.6506M
March 31, 2014 0.5494M

Revenues Definition

Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.

Read full definition.

Revenue (Quarterly) Range, Past 5 Years

View Revenue (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Revenue (Quarterly) Benchmarks

View Revenue (Quarterly) Benchmarks
Start Trial
ANI Pharmaceuticals, Inc. 266.04M
Corcept Therapeutics, Inc. 256.15M
Veru, Inc. 0.00
Johnson & Johnson 25.32B
Eli Lilly & Co. 22.97B